Sialorrhea in Parkinson's disease: prevalence, impact and management strategies

被引:12
|
作者
Miller, Nick [1 ]
Walshe, Margaret [2 ]
Walker, Richard W. [3 ]
机构
[1] Newcastle Univ, Inst Ageing Speech & Language Sci, George VI Bldg, Newcastle Upon Tyne NE1 7RU, England
[2] Univ Dublin, Trinity Coll Dublin, Clin Speech & Language Studies, Dublin 2, Ireland
[3] North Tyneside Gen Hosp, Dept Med, North Shields NE29 8NH, England
来源
关键词
drooling; Parkinson's; management; review; SALIVARY FLOW-RATE; QUALITY-OF-LIFE; DEEP BRAIN-STIMULATION; BOTULINUM-TOXIN-A; DOUBLE-BLIND; WORLD WORKSHOP; NONMOTOR SYMPTOMS; CONTROLLED-TRIAL; WHOLE SALIVA; ORAL-HEALTH;
D O I
10.2147/JPRLS.S177409
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Saliva plays an important part in oral health maintenance, mastication, deglutition and the start of the digestive process. It supports clear speech. Alterations to the composition and flow of saliva through hyper- or hyposecretion or anterior loss through the lips thus have potentially significant consequences. This article reviews the metrics, possible age and gender differences and diurnal variability of flow in healthy individuals. It then focuses on the ways in which this is altered in Parkinson's disease (PD) and the possible mechanisms for why people with PD drool. It reviews procedures for clinical assessment and management. Many studies report drooling prevalence >50% of people with PD, though in the early stages the impact may not yet be great. In PD, saliva flow is normal or even decreased compared to people without PD. Motorically sialorrhea arises from an interaction between oro-facial rigidity, lingual bradykinesia and aspects of oro-pharyngeal dysphagia. Postural, cognitive, attentional and pharmacological factors may also contribute. Objective evaluation of sialorrhea looks at the rate and variability of flow (milliliters or milligrams per unit time; swallow intervals; consistency). Since objective measures seldom reflect patient-reported lived experience, assessment includes rating scales that capture subjective concerns. Because altered salivary function impacts on (peri)oral health, assessment and monitoring of this is strongly advocated. Methods in each of these assessment domains are introduced. Clinical guidelines recommend behavioral interventions in the first instance, with pharmacological treatments, including botulinum injection, as follow-up possibilities. Surgical procedures are reserved for severe or intractable cases. High-quality evidence for the efficacy of behavioral interventions is lacking. Drug therapy efficacy is also under-studied, apart from botulinum toxin management. Few studies have examined surgical interventions in PD, though principles are well established from other populations. Strands of enquiry for improving our knowledge of behavioral interventions are suggested.
引用
收藏
页码:17 / 28
页数:12
相关论文
共 50 条
  • [1] Parkinson's disease-associated dysarthria: prevalence, impact and management strategies
    Moya-Gale, Gemma
    Levy, Erika S.
    [J]. RESEARCH AND REVIEWS IN PARKINSONISM, 2019, 9 : 9 - 16
  • [2] Sialorrhea in Parkinson's Disease
    Isaacson, Jonathan
    Patel, Sanskruti
    Torres-Yaghi, Yasar
    Pagan, Fernando
    [J]. TOXINS, 2020, 12 (11)
  • [3] Sialorrhea in Parkinson's disease: A review
    Chou, Kelvin L.
    Evatt, Marian
    Hinson, Vanessa
    Kompoliti, Katie
    [J]. MOVEMENT DISORDERS, 2007, 22 (16) : 2306 - 2313
  • [4] Dysphagia and sialorrhea associated with Parkinson's disease
    Nicaretta, D. H.
    Rosso, A. L. Z.
    de Mattos, J. P.
    Maliska, C.
    Nascimento, O. J. M.
    Novis, S. A. P.
    de Freitas, M. R.
    Moraes, M. A.
    Miliauskas, C. R.
    Campos, F. S.
    Bastos, L. T.
    Costa, M. M. B.
    [J]. MOVEMENT DISORDERS, 2010, 25 (07) : S333 - S333
  • [5] Glycopyrroniumbromide for the treatment of sialorrhea in Parkinson's disease
    Arbouw, M. E. L.
    Movig, K. L. L.
    Koopmann, M.
    Poels, P. J. E.
    Guchelaar, H. -J.
    Egberts, T. C. G.
    Neef, C.
    van Vugt, J. P. P.
    [J]. MOVEMENT DISORDERS, 2009, 24 : S255 - S255
  • [6] Glycopyrroniumbromide for the treatment of sialorrhea in parkinson's disease
    Arbouw, Maurits E. L.
    Movig, Kris L. L.
    Koopmann, Miriam
    Poels, Petra J. E.
    Guchelaar, Henk-Jan
    Egberts, Toine C. G.
    Neef, Cees
    van Vugt, Jeroen P. P.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (05) : 782 - 782
  • [7] Prevalence, impact, and management of depression and anxiety in patients with Parkinson's disease
    Renfroe, Jenna B.
    Turner, Travis H.
    Hinson, Vanessa K.
    [J]. JOURNAL OF PARKINSONISM AND RESTLESS LEGS SYNDROME, 2016, 6 : 15 - 22
  • [8] SIALORRHEA AND XEROSTOMIA IN PARKINSON'S DISEASE PATIENTS
    Spiljak, Bruno
    Lisak, Marijana
    Pasic, Hanna
    Trkanjec, Zlatko
    Huzjan, Arijana Lovrencic
    Kes, Vanja Basic
    [J]. ACTA CLINICA CROATICA, 2022, 61 (02) : 320 - 326
  • [9] Impact of continuous dopaminergic stimulation on Parkinson's disease management strategies
    Antonini, A.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 : 666 - 666
  • [10] LONG-TERM EFFICACY OF INCOBOTULINUMTOXINA IN THE MANAGEMENT OF SIALORRHEA IN PARKINSON'S DISEASE
    Ianieri, Giancarlo
    Marvulli, Riccardo
    Gallo, Giulia
    [J]. TOXICON, 2018, 156 : S45 - S46